RPT-BRIEF-U.S. FDA says approves Aveva's Onsolis for cancer

Repeating story with no changes to additional codes

WASHINGTON, July 16 (Reuters) - The U.S. Food and Drug
Administration:

* Says approves Onsolis, an opioid pain reliever for
certain cancer patients to manage breakthrough pain.

* Says Onsolis is made by Aveva and marketed under license
from BioDelivery Sciences International Inc (BDSI.O) by Meda
Pharmaceuticals.

* Says because Onsolis is in a class of drugs that deliver
fentanyl through mouth's mucous membranes, it was approved with
the requirement of a "risk evaluation and mitigation strategy"
or plan for managing risks with the drug.